JPH10513041A - 第21染色体遺伝子マーカー、これを使用する組成物および方法 - Google Patents
第21染色体遺伝子マーカー、これを使用する組成物および方法Info
- Publication number
- JPH10513041A JPH10513041A JP8516212A JP51621296A JPH10513041A JP H10513041 A JPH10513041 A JP H10513041A JP 8516212 A JP8516212 A JP 8516212A JP 51621296 A JP51621296 A JP 51621296A JP H10513041 A JPH10513041 A JP H10513041A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- ehoc
- seq
- dna
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 61
- 210000000349 chromosome Anatomy 0.000 title claims description 29
- 101150042997 21 gene Proteins 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 127
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 124
- 229920001184 polypeptide Polymers 0.000 claims abstract description 118
- 101000662690 Homo sapiens Trafficking protein particle complex subunit 10 Proteins 0.000 claims abstract description 98
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 84
- 102100037456 Trafficking protein particle complex subunit 10 Human genes 0.000 claims abstract description 80
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 69
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 62
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 62
- 239000000523 sample Substances 0.000 claims abstract description 46
- 230000027455 binding Effects 0.000 claims abstract description 20
- 239000013598 vector Substances 0.000 claims abstract description 19
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 15
- 230000009261 transgenic effect Effects 0.000 claims abstract description 15
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 11
- 238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 11
- 108020003175 receptors Proteins 0.000 claims abstract description 6
- 108020004414 DNA Proteins 0.000 claims description 62
- 210000004027 cell Anatomy 0.000 claims description 60
- 239000002299 complementary DNA Substances 0.000 claims description 56
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 27
- 108020004999 messenger RNA Proteins 0.000 claims description 23
- 238000009396 hybridization Methods 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 13
- 102000048498 human TRAPPC10 Human genes 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 238000013519 translation Methods 0.000 claims description 12
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 claims description 11
- 201000001204 progressive myoclonus epilepsy Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 238000013518 transcription Methods 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 210000000170 cell membrane Anatomy 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 5
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 4
- 210000003917 human chromosome Anatomy 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 239000002853 nucleic acid probe Substances 0.000 claims description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 3
- 108020005544 Antisense RNA Proteins 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 208000036878 aneuploidy Diseases 0.000 claims description 3
- 231100001075 aneuploidy Toxicity 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 239000012051 hydrophobic carrier Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 238000010188 recombinant method Methods 0.000 claims description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108700019146 Transgenes Proteins 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 108020004491 Antisense DNA Proteins 0.000 claims 2
- 239000003816 antisense DNA Substances 0.000 claims 2
- 206010009346 Clonus Diseases 0.000 claims 1
- 239000003155 DNA primer Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000013615 primer Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 239000006152 selective media Substances 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 34
- 102000005962 receptors Human genes 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 16
- 239000005557 antagonist Substances 0.000 description 11
- 238000013507 mapping Methods 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 201000010374 Down Syndrome Diseases 0.000 description 9
- 108091034057 RNA (poly(A)) Proteins 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 230000001605 fetal effect Effects 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 208000033255 Progressive myoclonic epilepsy type 1 Diseases 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 7
- 102100026891 Cystatin-B Human genes 0.000 description 7
- 101000912191 Homo sapiens Cystatin-B Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 206010044688 Trisomy 21 Diseases 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000003298 DNA probe Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 201000008665 holoprosencephaly 1 Diseases 0.000 description 6
- 238000007901 in situ hybridization Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 102100032921 ATP-dependent 6-phosphofructokinase, liver type Human genes 0.000 description 5
- 102100036465 Autoimmune regulator Human genes 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 101000730830 Homo sapiens ATP-dependent 6-phosphofructokinase, liver type Proteins 0.000 description 5
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 101710172814 Sodium channel protein Proteins 0.000 description 5
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 5
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 4
- 102100025390 Integrin beta-2 Human genes 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000010187 selection method Methods 0.000 description 4
- 230000005026 transcription initiation Effects 0.000 description 4
- 102000035160 transmembrane proteins Human genes 0.000 description 4
- 108091005703 transmembrane proteins Proteins 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RURLVUZRUFHCJO-UHFFFAOYSA-N Chromomycin A3 Natural products COC(C1Cc2cc3cc(OC4CC(OC(=O)C)C(OC5CC(O)C(OC)C(C)O5)C(C)O4)c(C)c(O)c3c(O)c2C(=O)C1OC6CC(OC7CC(C)(O)C(OC(=O)C)C(C)O7)C(O)C(C)O6)C(=O)C(O)C(C)O RURLVUZRUFHCJO-UHFFFAOYSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004129 prosencephalon Anatomy 0.000 description 3
- 210000000449 purkinje cell Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- -1 Motors Substances 0.000 description 2
- 101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102000018674 Sodium Channels Human genes 0.000 description 2
- 108010052164 Sodium Channels Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 108010042747 stallimycin Proteins 0.000 description 2
- 229950009902 stallimycin Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- UXUFTKZYJYGMGO-CMCWBKRRSA-N (2s,3s,4r,5r)-5-[6-amino-2-[2-[4-[3-(2-aminoethylamino)-3-oxopropyl]phenyl]ethylamino]purin-9-yl]-n-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(=O)NCCN)=CC=3)=NC(N)=C2N=C1 UXUFTKZYJYGMGO-CMCWBKRRSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- NGYHUCPPLJOZIX-XLPZGREQSA-N 5-methyl-dCTP Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NGYHUCPPLJOZIX-XLPZGREQSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 102100034278 Annexin A6 Human genes 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001672577 Baku virus Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000011297 Brassica napobrassica Nutrition 0.000 description 1
- 241000219192 Brassica napus subsp. rapifera Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100124476 Caenorhabditis elegans ceh-18 gene Proteins 0.000 description 1
- 101100231507 Caenorhabditis elegans ceh-2 gene Proteins 0.000 description 1
- 101100178168 Caenorhabditis elegans ceh-33 gene Proteins 0.000 description 1
- 101100028482 Caenorhabditis elegans pal-1 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108700002847 Drosophila Rut Proteins 0.000 description 1
- 108700009756 Drosophila pros Proteins 0.000 description 1
- 108700023950 Drosophila sev Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000006360 Edwards syndrome Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000801195 Homo sapiens TLE family member 5 Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 201000009928 Patau syndrome Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000020424 Polyglandular disease Diseases 0.000 description 1
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102220524169 Receptor-interacting serine/threonine-protein kinase 1_D21S_mutation Human genes 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 1
- 101100384866 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COT1 gene Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 241000013033 Triso Species 0.000 description 1
- 206010044686 Trisomy 13 Diseases 0.000 description 1
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 1
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 1
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 description 1
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003141 anti-fusion Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 208000025341 autosomal recessive disease Diseases 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 101150051158 ceh-30 gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000003372 electrophysiological method Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- 230000010502 episomal replication Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108010081400 fluorescein isothiocyante avidin Proteins 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 102000056245 human TLE5 Human genes 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000000782 polymeric membrane extraction Methods 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010053884 trisomy 18 Diseases 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ヒトEHOC−1ポリペプチドをコードする、単離された核酸。 2.核酸はDNAを含んでなる、請求項1記載の単離された核酸。 3.DNAはcDNAである、請求項2記載のDNA。 4.DNAは、配列番号:2に記載のアミノ酸配列をコードする、請求項2記 載のDNA。 5.DNAは、高厳密性条件下で配列番号:1または配列番号:6に記載の実 質的に全てのコード配列(ヌクレオチド138〜3710)にハイブリダイズす る、請求項2記載のDNA。 6.DNAは、配列番号:1または配列番号:6に記載のヌクレオチド配列と 実質的に同じヌクレオチド配列を有する、請求項2記載のDNA。 7.請求項2記載のDNAを含んでなるベクター。 8.細胞は原核細胞または真核細胞である、請求項7記載のベクターを含有す る宿主細胞。 9.細胞は機能性EHOC−1タンパク質を発現する、請求項8記載の宿主細 胞。 10.配列番号:1または配列番号:6に記載のヌクレオチド配列の核酸の配列 と特異的にハイブリダイズすることができる、少なくとも15ヌクレオチドを含 んでなる核酸プローブ。 11.プローブは検出可能なマーカーで標識される、請求項10記載の核酸プロ ーブ。 12.複数のプローブを含んでなる、遺伝子座q22.3で第21染色体の突然 変異および異数性を検出するためのキットであって、各プローブは、配列番号: 1または配列番号:6に記載のヌクレオチド配列の核酸の配列と特異的にハイブ リダイズすることができる、少なくとも15塩基対の隣接ヌクレオチドを有する 核酸配列を含んでなり、各プローブは、染色体21q22.3上の特異的遺伝子 座に対応する、上記キット。 13.請求項2記載のDNAに相補的な単離されたmRNA。 14.RNA転写のプロモーターに機能的に結合している、請求項2記載の核酸 の化学的類似体を含んでなるオリゴヌクレオチド組成物。 15.請求項13記載のmRNAに特異的に結合することができ、その翻訳を調 節することができる、アンチセンスオリゴヌクレオチド。 16.単離されたEHOC−1ポリペプチドおよびその機能性同等物。 17.ポリペプチドは、配列番号:2に記載のものと実質的に同じアミノ酸配列 を有する、請求項16記載の単離されたEHOC−1ポリペプチド。 18.ポリペプチドは、配列番号:2に記載のものと同じアミノ酸配列を有する 、請求項16記載の単離されたEHOC−1ポリペプチド。 19.ポリペプチドは、配列番号:1または配列番号:6に記載のものと実質的 に同じヌクレオチド配列であるヌクレオチド配列によりコードされる、請求項1 6記載の単離されたEHOC−1ポリペプチド。 20.ポリペプチドは、配列番号:1または配列番号:6に記載のヌクレオチド 配列によりコードされる、請求項16記載の単離されたEHOC−1ポリペプチ ド。 21.組換え法で宿主細胞中で発現されるEHOC−1ポリペプチド。 22.ポリペプチドは、配列番号:1または配列番号:6に記載のものと実質的 に同じヌクレオチド配列であるヌクレオチド配列によりコードされる、請求項2 1記載のEHOC−1ポリペプチド。 23.ポリペプチドは、配列番号:1または配列番号:6に記載のヌクレオチド 配列によりコードされる、請求項21記載のEHOC−1ポリペプチド。 24.ヒトEHOC−1タンパク質上の抗原決定基に特異的に結合する抗体また はその活性断片。 25.抗体はモノクローナル抗体である、請求項24記載の抗体。 26.抗体はポリクローナル抗体である、請求項24記載の抗体。 27.ヒトEHOC−1ポリペプチドの発現を調節するのに有効な量の請求項1 3記載のアンチセンスオリゴヌクレオチドと、細胞膜を通過することができる許 容される疎水性担体を含んでなる組成物。 28.オリゴヌクレオチドは、mRNAを不活性化する物質に結合している、請 求項27記載の組成物。 29.物質はリボザイムである、請求項28記載の組成物。 30.ヒトEHOC−1受容体に対する天然に存在するリガンドへの結合を阻止 するのに有効な量の請求項24記載の抗体と、許容される担体を含んでなる組成 物。 31.ヒトEHOC−1ポリペプチドをコードするDNAを発現するトランスジ ェニック非ヒト哺乳動物。 32.ポリペプチドをコードするDNAは、正常ポリペプチド活性を示すことが できないように突然変異され、発現されたポリペプチドは未変性のEHOC−1 ポリペプチドではない、請求項31記載のトランスジェニック非ヒト哺乳動物。 33.アンチセンスDNAは、ヒトEHOC−1ポリペプチドをコードするmR NAに相補的なアンチセンスmRNAに転写される、そのゲノムが、ヒトEHO C−1ポリペプチドをコードするDNAに相補的なアンチセンスDNAを含んで なるトランスジェニック非ヒト哺乳動物。 34.DNAは誘導性プロモーターに機能的に結合している、請求項31記載の トランスジェニック非ヒト哺乳動物。 35.DNAは組織特異的制御成分に機能的に結合している、請求項31記載の トランスジェニック非ヒト哺乳動物。 36.トランスジェニック非ヒト哺乳動物はマウスである、請求項31記載のト ランスジェニック非ヒト哺乳動物。 37.ヒトEHOC−1タンパク質をコードする核酸の同定方法であって、核酸 を含有する試料に請求項11記載のプローブを接触させ、ここで、接触は高厳密 性ハイブリダイゼーション条件下で行われる、これにハイブリダイズする化合物 を同定することからなる、上記方法。 38.請求項9記載の細胞に化合物を接触させ、これに結合する化合物を同定す ることからなる、ヒトEHOC−1ポリペプチドに結合する化合物の同定方法。 39.細胞表面上のヒトEHOC−1ポリペプチドの存在の検出方法であって、 試験細胞に請求項24記載の抗体を接触させ、抗体−受容体複合体の存在を検出 し、そして細胞表面上のヒトEHOC−1ポリペプチドの存在を検出することか らなる、上記方法。 40.特異的なヒトEHOC−1ポリペプチドアレルの発現に関連する疾患への 罹り易さを診断する方法であって、該方法は、核酸を含有する試料に複数のプロ ーブを接触させることからなり、各プローブは、配列番号:1または配列番号: 6記載のヌクレオチド配列の核酸の配列と特異的にハイブリダイズすることがで きる、少なくとも15塩基対の隣接ヌクレオチドを有する核酸配列を含んでなり 、各プローブは染色体21q22.3上の特異的遺伝子座に対応する、上記方法 。 41.疾患は、進行性ミオクローヌスてんかん、全前脳症、または自己免疫多腺 性疾患から選択される、請求項40記載の方法。 42.遺伝子の発現を調節する組成物を投与することからなる、特定の疾患に関 連した症状の発生を検出する方法。 43.ヒト染色体座21q22.3に変化を導入する方法であって、進行性ミオ クローヌスてんかんを有する被験体から得られた細胞の試料を、選択性マーカー 遺伝子とともに請求項1記載の核酸で形質転換し;選択培地で細胞を維持し;そ して、修飾された標的配列を含有する生存細胞を単離する、ことからなる上記方 法。 44.野生型EHOC−1遺伝子またはその機能性断片を、発現されるように細 胞内に導入することからなる、EHOC−1遺伝子内で突然変異/異数性を有す る該細胞に野生型EHOC−1遺伝子機能を付与する方法。 45.プライマーは、配列番号:1、配列番号:5または配列番号:6に記載の 核酸配列から得られた核酸配列を含んでなる、進行性ミオクローヌスてんかんの 増幅診断のための1本鎖DNAプライマー。 46.任意のBACクローン中に含有される遺伝子内の変種ヌクレオチド配列の 有無を測定することからなる、核酸試料中の1つまたはそれ以上のEHOC−1 アレルの検出方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/337,690 | 1994-11-09 | ||
US08/337,690 US5773268A (en) | 1994-11-09 | 1994-11-09 | Chromosome 21 gene marker, compositions and methods using same |
PCT/US1995/014641 WO1996015144A2 (en) | 1994-11-09 | 1995-11-08 | Chromosome 21 gene marker, compositions and methods using same |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10513041A true JPH10513041A (ja) | 1998-12-15 |
Family
ID=23321594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8516212A Ceased JPH10513041A (ja) | 1994-11-09 | 1995-11-08 | 第21染色体遺伝子マーカー、これを使用する組成物および方法 |
Country Status (5)
Country | Link |
---|---|
US (3) | US5773268A (ja) |
EP (1) | EP0796274A2 (ja) |
JP (1) | JPH10513041A (ja) |
CN (1) | CN1131240C (ja) |
WO (1) | WO1996015144A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6593086B2 (en) * | 1996-05-20 | 2003-07-15 | Mount Sinai School Of Medicine Of New York University | Nucleic acid amplification methods |
US6951928B1 (en) * | 1997-10-02 | 2005-10-04 | National Public Health Institute | Nucleic acid molecule encoding a (poly)peptide co-segregating in mutated form with Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED) |
US8337753B2 (en) | 1998-05-01 | 2012-12-25 | Gen-Probe Incorporated | Temperature-controlled incubator having a receptacle mixing mechanism |
EP1930078A1 (en) | 1998-05-01 | 2008-06-11 | Gen-Probe Incorporated | Method for agitating the contents of a container |
AU2006230728B8 (en) * | 1998-05-01 | 2008-10-02 | Gen-Probe Incorporated | Incubator for use in an automated diagnostic analyzer |
WO2000012526A1 (en) * | 1998-08-28 | 2000-03-09 | Princeton University | NOVEL TARGETS OF p53 REGULATORY ACTIVITY |
WO2006099255A2 (en) | 2005-03-10 | 2006-09-21 | Gen-Probe Incorporated | Systems and methods to perform assays for detecting or quantifying analytes within samples |
WO2010111198A1 (en) * | 2009-03-23 | 2010-09-30 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
CN103675303B (zh) | 2010-07-23 | 2016-02-03 | 贝克曼考尔特公司 | 传感器系统 |
US9046507B2 (en) | 2010-07-29 | 2015-06-02 | Gen-Probe Incorporated | Method, system and apparatus for incorporating capacitive proximity sensing in an automated fluid transfer procedure |
EP2678664B1 (en) | 2011-02-24 | 2019-08-07 | Gen-Probe Incorporated | Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector |
ES2778054T3 (es) | 2011-11-07 | 2020-08-07 | Beckman Coulter Inc | Sistema y método para transportar recipientes de muestras |
US9482684B2 (en) | 2011-11-07 | 2016-11-01 | Beckman Coulter, Inc. | Centrifuge system and workflow |
US9446418B2 (en) | 2011-11-07 | 2016-09-20 | Beckman Coulter, Inc. | Robotic arm |
EP2776846B1 (en) | 2011-11-07 | 2019-08-21 | Beckman Coulter, Inc. | Aliquotter system and workflow |
JP2014532881A (ja) | 2011-11-07 | 2014-12-08 | ベックマン コールター, インコーポレイテッド | 標本輸送システムのための磁気制動 |
EP2776844B1 (en) | 2011-11-07 | 2020-09-30 | Beckman Coulter, Inc. | Specimen container detection |
ES2934684T3 (es) | 2013-03-15 | 2023-02-24 | Abbott Lab | Analizadores de diagnóstico automatizados que tienen carruseles dispuestos verticalmente y métodos relacionados |
CN114137240A (zh) | 2013-03-15 | 2022-03-04 | 雅培制药有限公司 | 具有后面可进入轨道系统的自动化诊断分析仪及相关方法 |
WO2014149118A2 (en) | 2013-03-15 | 2014-09-25 | Abbott Laboratories | Diagnostic analyzers with pretreatment carousels and related methods |
CN103699815B (zh) * | 2014-01-10 | 2017-06-13 | 北京林业大学 | 一种同源四倍体自然群体的连锁不平衡分析模型的构建方法 |
US10427162B2 (en) | 2016-12-21 | 2019-10-01 | Quandx Inc. | Systems and methods for molecular diagnostics |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756348A (en) * | 1991-11-12 | 1998-05-26 | Synaptic Pharmaceutical Corporation | DNA encoding a glycine transporter and uses thereof |
-
1994
- 1994-11-09 US US08/337,690 patent/US5773268A/en not_active Expired - Fee Related
-
1995
- 1995-11-08 WO PCT/US1995/014641 patent/WO1996015144A2/en not_active Application Discontinuation
- 1995-11-08 CN CN95196064A patent/CN1131240C/zh not_active Expired - Fee Related
- 1995-11-08 EP EP95939885A patent/EP0796274A2/en not_active Withdrawn
- 1995-11-08 JP JP8516212A patent/JPH10513041A/ja not_active Ceased
-
1998
- 1998-03-26 US US09/048,887 patent/US6166180A/en not_active Expired - Fee Related
-
2000
- 2000-12-26 US US09/749,273 patent/US20040180335A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040180335A1 (en) | 2004-09-16 |
US6166180A (en) | 2000-12-26 |
CN1166837A (zh) | 1997-12-03 |
EP0796274A2 (en) | 1997-09-24 |
WO1996015144A2 (en) | 1996-05-23 |
US5773268A (en) | 1998-06-30 |
CN1131240C (zh) | 2003-12-17 |
WO1996015144A3 (en) | 1996-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10513041A (ja) | 第21染色体遺伝子マーカー、これを使用する組成物および方法 | |
US5776677A (en) | Methods of detecting cystic fibrosis gene by nucleic acid hybridization | |
JPH06128294A (ja) | アミロイド前駆体様タンパク質及びその使用 | |
IE903024A1 (en) | Cystic fibrosis gene | |
WO1997042314A1 (en) | Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto | |
US8975018B2 (en) | Method of detecting expanded CAG repeat region in spinocerebellar ataxia-2 gene | |
JP3449419B2 (ja) | KVLQT1をコードするQT延長症候群遺伝子およびそのminKとの関連 | |
EP1108026B1 (en) | Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same | |
WO1998059050A1 (en) | Cloning of a gene mutation for parkinson's disease | |
US6844431B1 (en) | Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto | |
US6040429A (en) | Congenital heart disease proteins and products related thereto | |
US20040248247A1 (en) | Bhlh-pas proteins, genes thereof and utilization of the same | |
WO1997017437A2 (en) | A chromosome 21 - derived nucleic acid encoding a novel protein, compositions and method using same | |
US6960656B1 (en) | Nucleic acid encoding DS-CAM proteins and products related thereto | |
WO1998017795A1 (en) | Nucleic acid encoding ds-cam proteins and products related thereto | |
CA2403547A1 (en) | Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same | |
WO2000044783A1 (fr) | Proteine meg 4 | |
EP1209231A1 (en) | Meg-1 protein | |
JP2005525079A (ja) | Als2遺伝子と筋萎縮性側索硬化症2型 | |
US20030022208A1 (en) | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof | |
FR2800388A1 (fr) | Clonage, expression et caracterisation d'un gene exprime dans des cellules tumorales et implique dans la regulation de la reponse immune | |
WO2002062835A1 (en) | Nucleic acids and polypeptides for controlling food intake and/or body weight | |
JPH09221499A (ja) | 神経細胞で発現する新規タンパク質 | |
WO2001029266A2 (en) | Identification of arsacs mutations and methods of use therefor | |
AU4807001A (en) | Ovary-specific genes and proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050222 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050523 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050704 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20050926 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051101 |